BAYRY Stock Recent News

Bayer A.G.'s stock is very cheap and near multi-year lows, but ongoing declines and uncertain turnaround make it risky for conservative investors. Pharmaceuticals and consumer health divisions are showing rising sales, while crop science is under pressure and facing regulatory risks, especially with glyphosate. Recent earnings disappointed, with declining profitability and net losses, but operational cash flow has improved, and sales remain stable.

Bayer is seeking to resolve lawsuits related to its Roundup weedkiller, while exploring a bankruptcy for its Monsanto unit if the settlement plan fails, the Wall Street Journal reported on Thursday, citing people familiar with the matter.

The agricultural giant is preparing to place its U.S. subsidiary Monsanto in bankruptcy if a settlement with tort plaintiffs fails

Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for reviews despite recent job cuts and a restructuring.

Bayer AG BAYRY reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago.

Bayer A.G. (OTCPK:BAYZF) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Rodrigo Santos - President, Crop Science Division Stefan Oelrich - President, Pharmaceuticals Division Conference Call Participants Richard Vosser - JPMorgan Sachin Jain - Bank of America Merrill Lynch James Quigley - Goldman Sachs Jo Walton - UBS Christian Feitz - Kepler Cheuvreux Vincent Andrews - Morgan Stanley Laurent Favre - BNP Paribas Operator Good afternoon and good morning, everybody, and welcome to our conference call to discuss the first quarter results for 2025. To kick things off, Bill will share insights on our overall business performance and the progress we've made on our strategic priorities thus far.

BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.

Bayer said on Tuesday that the U.S. Supreme Court could decide as early as next month whether it will hear the German company's request to sharply limit litigation that could run into the billions of dollars over disputed claims that its Roundup weedkiller causes cancer.

Bayer on Tuesday posted a slower decline in first-quarter adjusted earnings than the market had feared as strong prescription numbers for new drugs offset a drop in its soy and cotton seed business.

The company stuck to its full-year outlook on better-than-expected sales and adjusted earnings, but posted a fall in net profit.